AI-Generated Summary

A Chinese biotech firm's novel cancer drug, ivonescimab, has achieved superior results in late-stage clinical trials for non-small-cell lung cancer, outperforming Merck's Keytruda. This success is drawing global attention and is viewed as a significant milestone for China's burgeoning biopharmaceutical sector. However, experts caution that while domestic drug-creation prowess is rising, consistently delivering truly novel breakthroughs remains a challenge.

In a nutshell

This piece highlights the increasing global competitiveness in drug development, showcasing how emerging biotech hubs like China are producing clinically significant innovations. It underscores the dynamic shifts in the pharmaceutical landscape and the potential for new players to redefine market leadership.

Source: South China Morning Post